MDCG guidance
SCHEER guidelines: Update on the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties
MDCG guidance · Other guidance documents · June 2024
Key facts
| Reference | SCHEER guidelines |
|---|---|
| Title | Update on the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties |
| Topic | Other guidance documents |
| Published | June 2024 |
| Document | health.ec.europa.eu |
At a glance
- Yes Full text searchable in Orca1
- SCHEER guidelines (June 2024) Revisions on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About MDCG guidance documents
The Medical Device Coordination Group (MDCG), made up of EU member-state experts, endorses guidance on applying the Medical Devices Regulation (EU) 2017/745 and the In Vitro Diagnostic Regulation (EU) 2017/746. Each page here covers one document and all of its revisions.